Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Lancet (London, England), Volume 358, Issue 9295, 2001, Pages 1754-1759.
growth hormone receptor
Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days.Treatment efficacy was ass...More
Full Text (Upload PDF)
PPT (Upload PPT)